Phase I Double-blind, Placebo-controlled Study of AZD7442

Phase 1

Completed

• Conditions: COVID-19
• Interventions: Biological: AZD7442 300 mg IM(male); Biological: AZD7442 600 mg IM (male); Biological: AZD7442 300 mg IV (male and female); Biological: AZD7442 1000 mg IV (male)

• Registration Number: NCT04896541
• Lead Sponsor: AstraZeneca

Brief Summary

AZD7442 mAbs are being evaluated for administration to prevent or treat COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD7442.

Detailed Description

Severe acute respiratory coronavirus 2 is a novel coronavirus that appears to have first emerged in China in November 2019 causing cases of atypical pneumonia. Since then, the COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. As of 22 December 2020, the virus had spread to all corners of the globe, involving 218 countries/regions with over 78.00 million confirmed cases reported and more than 1.71 million associated deaths. As a response to the ongoing pandemic, AstraZeneca is developing mAbs to the SARS-CoV-2 spike protein. The SARS-CoV-2 spike protein contains the virus's receptor binding domain, which enables the virus to bind to receptors on human cells. By targeting this region of the virus's spike protein, antibodies can block the virus's attachment to human cells, and, therefore, are expected to block infection. AZD7442, a combination of 2 of these mAbs (AZD8895 and AZD1061), is being evaluated for administration to treat or prevent COVID-19. There are currently one ongoing Phase I study and two ongoing Phase III studies with AZD7442, in addition to this treatment study.

Randomization of approximately 40 Japanese participants is planned.

Study Timeline

• Study First Submitted: 2021-02-26
• Study Start: 2021-03-16
• Study First Submitted QC: 2021-05-20
• Study First Posted: 2021-05-21
• Status Verified: 2022-06
• Primary Completion: 2022-06-14
• Study Completion: 2022-06-14
• Last Update Submitted: 2022-06-24
• Last Update Posted: 2022-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Participants must be Japanese men and women and 18 to 55 years of age inclusive, at the time of signing the informed consent.
• Negative results from both SARS-CoV-2 qRT-PCR and serology tests
• Healthy by medical history, physical examination, and safety laboratory tests, according to the judgement of the investigators

Exclusion Criteria

• Fever above 37.5°C by the time when the participant is randomised; a participant excluded for transient acute illness may be dosed if the illness resolves by the time of randomisation.
• History of infection with SARS or MERS
• Any drug therapy within 7 days prior to Day 1

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AZD7442	AZD7442 300 mg IV (male and female)	Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
AZD7442	AZD7442 300 mg IM(male)	Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
AZD7442	AZD7442 600 mg IM (male)	Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
AZD7442	AZD7442 1000 mg IV (male)	Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
placebo	AZD7442 300 mg IM(male)	Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
placebo	AZD7442 600 mg IM (male)	Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
placebo	AZD7442 300 mg IV (male and female)	Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
placebo	AZD7442 1000 mg IV (male)	Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.

Primary Outcome Measures

Name	Time	Method
Adverse event and serious adverse event	Up to Day361	To evaluate the safety and tolerability of AZD7442 administered IV or IM_Adverse event and serious adverse event
Pharmacokinetics - Serum Concentration	Up to Day361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics - Area under the plasma concentration-time curve to the last measurable time point	Up to Day361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics - Maximum Serum Concentration	Up to Day361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics - Time to Maximum Serum Concentration	Up to Day361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics - Area under the plasma concentration-time curve extrapolated to infinity	Up to Day361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics -extravascular terminal phase volume of distribution	Up to Day361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics - extravascular systemic clearance	Up to 361	To evaluate the single-dose PK of AZD7442.
Pharmacokinetics -bioavailability	Up to Day361	To evaluate the single-dose PK of AZD7442.

Secondary Outcome Measures

Name	Time	Method
The serum neutralizing responses against SARS-CoV-2 using Geometric mean fold rise from baseline	Up to Day361	Blood samples as neutralizing responses against SARS-CoV-2 in serum will be collected.
ADA responses to the AZD7442 in serum.	Up to Day361	Blood samples for determination of ADA in serum will be assayed by bioanalytical test sites, using an appropriately validated bioanalytical method.
The serum neutralizing responses against SARS-CoV-2 using Geometric mean titre from baseline	Up to Day361	Blood samples as neutralizing responses against SARS-CoV-2 in serum will be collected.

Trial Locations

Locations (1)

Research Site; 🇯🇵 Fukuoka-shi, Japan